Naveglitazar | CAS#476436-68-7 | peroxisome proliferator-activated receptor (PPAR) modulator |MedKoo

MedKoo Cat#: 319623 | Name: Naveglitazar

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Naveglitazar, also known as LY 519818, LY 9818, is a peroxisome proliferator-activated receptor (PPAR) modulator, had been in phase II clinical trials for the once-daily oral treatment of type 2 diabetes, however, no recent development for this indication has been reported.

Chemical Structure

Naveglitazar

CAS#476436-68-7

Theoretical Analysis

MedKoo Cat#: 319623

Name: Naveglitazar

CAS#: 476436-68-7

Chemical Formula: C25H26O6

Exact Mass: 422.1729

Molecular Weight: 422.48

Elemental Analysis: C, 71.07; H, 6.20; O, 22.72

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

LY519818; LY-519818; LY 519818; LY-9818; LY9818; LY 9818; CCRIS 9448; Naveglitazar.

IUPAC/Chemical Name

(S)-2-methoxy-3-(4-(3-(4-phenoxyphenoxy)propoxy)phenyl)propanoic acid

InChi Key

OKJHGOPITGTTIM-DEOSSOPVSA-N

InChi Code

InChI=1S/C25H26O6/c1-28-24(25(26)27)18-19-8-10-20(11-9-19)29-16-5-17-30-21-12-14-23(15-13-21)31-22-6-3-2-4-7-22/h2-4,6-15,24H,5,16-18H2,1H3,(H,26,27)/t24-/m0/s1

SMILES Code

O=C(O)[C@@H](OC)CC1=CC=C(OCCCOC2=CC=C(OC3=CC=CC=C3)C=C2)C=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 422.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Tseng CH, Tseng FH. Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2012;30(4):368-402. doi: 10.1080/10590501.2012.735519. Review. PubMed PMID: 23167631. 2: Long GG, Reynolds VL, Dochterman LW, Ryan TE. Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR alpha/gamma agonist. Toxicol Pathol. 2009 Oct;37(6):741-53. doi: 10.1177/0192623309343775. Epub 2009 Aug 21. PubMed PMID: 19700659. 3: Ahlawat P, Srinivas NR. Allometric prediction of the human pharmacokinetic parameters for naveglitazar. Eur J Drug Metab Pharmacokinet. 2008 Jul-Sep;33(3):187-90. PubMed PMID: 19007045. 4: Long GG, Reynolds VL, Lopez-Martinez A, Ryan TE, White SL, Eldridge SR. Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event. Toxicol Pathol. 2008 Feb;36(2):218-31. doi: 10.1177/0192623307311757. PubMed PMID: 18474944. 5: Yi P, Hadden CE, Annes WF, Jackson DA, Peterson BC, Gillespie TA, Johnson JT. The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor alpha-gamma dual, gamma-dominant agonist in mice, rats, and monkeys. Drug Metab Dispos. 2007 Jan;35(1):51-61. Epub 2006 Sep 29. PubMed PMID: 17012539.